Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for NovaBay Pharmaceuticals (NBY) over the last 12 years, with Q2 2020 value amounting to $118000.0.

  • NovaBay Pharmaceuticals' Current Deferred Revenue changed N/A to $118000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $118000.0, marking a year-over-year change of. This contributed to the annual value of $41000.0 for FY2019, which is 5940.59% down from last year.
  • As of Q2 2020, NovaBay Pharmaceuticals' Current Deferred Revenue stood at $118000.0.
  • In the past 5 years, NovaBay Pharmaceuticals' Current Deferred Revenue registered a high of $2.5 million during Q3 2017, and its lowest value of $41000.0 during Q4 2019.
  • In the last 5 years, NovaBay Pharmaceuticals' Current Deferred Revenue had a median value of $559000.0 in 2020 and averaged $869933.3.
  • In the last 5 years, NovaBay Pharmaceuticals' Current Deferred Revenue soared by 62409.09% in 2016 and then plummeted by 9626.06% in 2018.
  • NovaBay Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $1.9 million in 2016, then crashed by 95.97% to $75000.0 in 2017, then soared by 34.67% to $101000.0 in 2018, then plummeted by 59.41% to $41000.0 in 2019, then skyrocketed by 187.8% to $118000.0 in 2020.
  • Its Current Deferred Revenue was $118000.0 in Q2 2020, compared to $559000.0 in Q1 2020 and $41000.0 in Q4 2019.